2023 Q3 Form 10-Q Financial Statement
#000095017023037996 Filed on August 03, 2023
Income Statement
Concept | 2023 Q3 | 2023 Q2 |
---|---|---|
Revenue | $11.99M | $13.59M |
YoY Change | -9.6% | -3.11% |
Cost Of Revenue | ||
YoY Change | ||
Gross Profit | ||
YoY Change | ||
Gross Profit Margin | ||
Selling, General & Admin | $29.40M | $30.65M |
YoY Change | 32.76% | 38.5% |
% of Gross Profit | ||
Research & Development | $113.7M | $115.3M |
YoY Change | 17.64% | 27.8% |
% of Gross Profit | ||
Depreciation & Amortization | $2.290M | $2.170M |
YoY Change | 17.44% | 18.13% |
% of Gross Profit | ||
Operating Expenses | $113.7M | $115.3M |
YoY Change | 17.64% | 27.8% |
Operating Profit | -$131.1M | -$132.3M |
YoY Change | 24.24% | 34.62% |
Interest Expense | $8.880M | $8.653M |
YoY Change | 7900.0% | -439.47% |
% of Operating Profit | ||
Other Income/Expense, Net | $8.883M | $8.653M |
YoY Change | -215.38% | -464.03% |
Pretax Income | -$122.2M | -$123.7M |
YoY Change | 7.94% | 22.85% |
Income Tax | ||
% Of Pretax Income | ||
Net Earnings | -$122.2M | -$123.7M |
YoY Change | 7.94% | 22.85% |
Net Earnings / Revenue | -1019.21% | -909.82% |
Basic Earnings Per Share | -$1.38 | -$1.40 |
Diluted Earnings Per Share | -$1.38 | -$1.40 |
COMMON SHARES | ||
Basic Shares Outstanding | 88.49M | 88.14M |
Diluted Shares Outstanding | 88.65M | 88.19M |
Balance Sheet
Concept | 2023 Q3 | 2023 Q2 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $854.8M | $908.1M |
YoY Change | 3.21% | 3.87% |
Cash & Equivalents | $168.0M | $171.8M |
Short-Term Investments | $686.8M | $736.3M |
Other Short-Term Assets | $32.20M | $26.49M |
YoY Change | 20.46% | 44.7% |
Inventory | ||
Prepaid Expenses | ||
Receivables | $6.491M | $5.056M |
Other Receivables | $0.00 | $0.00 |
Total Short-Term Assets | $893.5M | $939.6M |
YoY Change | 4.02% | 4.93% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $33.80M | $33.19M |
YoY Change | 27.08% | 28.32% |
Goodwill | ||
YoY Change | ||
Intangibles | ||
YoY Change | ||
Long-Term Investments | $17.17M | $21.84M |
YoY Change | -57.19% | -52.13% |
Other Assets | $42.40M | $41.03M |
YoY Change | 14.63% | 10.51% |
Total Long-Term Assets | $349.9M | $383.6M |
YoY Change | 55.14% | 78.44% |
TOTAL ASSETS | ||
Total Short-Term Assets | $893.5M | $939.6M |
Total Long-Term Assets | $349.9M | $383.6M |
Total Assets | $1.243B | $1.323B |
YoY Change | 14.65% | 19.17% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $3.553M | $11.63M |
YoY Change | -18.96% | 54.81% |
Accrued Expenses | $57.98M | $49.53M |
YoY Change | -0.69% | 10.39% |
Deferred Revenue | $13.35M | $21.93M |
YoY Change | -75.65% | -64.51% |
Short-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Long-Term Debt Due | ||
YoY Change | ||
Total Short-Term Liabilities | $91.95M | $99.85M |
YoY Change | -29.88% | -19.32% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Other Long-Term Liabilities | $114.0M | $118.5M |
YoY Change | -11.2% | 998.25% |
Total Long-Term Liabilities | $114.0M | $118.5M |
YoY Change | -11.2% | 998.25% |
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $91.95M | $99.85M |
Total Long-Term Liabilities | $114.0M | $118.5M |
Total Liabilities | $205.9M | $218.4M |
YoY Change | -20.64% | 62.28% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$1.526B | -$1.404B |
YoY Change | 43.47% | 47.7% |
Common Stock | $2.567B | $2.513B |
YoY Change | 35.25% | 36.51% |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $1.037B | $1.105B |
YoY Change | ||
Total Liabilities & Shareholders Equity | $1.243B | $1.323B |
YoY Change | 14.65% | 19.17% |
Cashflow Statement
Concept | 2023 Q3 | 2023 Q2 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | -$122.2M | -$123.7M |
YoY Change | 7.94% | 22.85% |
Depreciation, Depletion And Amortization | $2.290M | $2.170M |
YoY Change | 17.44% | 18.13% |
Cash From Operating Activities | -$101.4M | -$90.32M |
YoY Change | 29.1% | 6.15% |
INVESTING ACTIVITIES | ||
Capital Expenditures | $4.340M | $4.301M |
YoY Change | -202.43% | -208.07% |
Acquisitions | ||
YoY Change | ||
Other Investing Activities | $83.83M | -$30.24M |
YoY Change | 61.58% | -130.44% |
Cash From Investing Activities | $79.50M | -$34.54M |
YoY Change | 66.87% | -136.22% |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | 19.10M | 2.516M |
YoY Change | -20.34% | -57.32% |
NET CHANGE | ||
Cash From Operating Activities | -101.4M | -90.32M |
Cash From Investing Activities | 79.50M | -34.54M |
Cash From Financing Activities | 19.10M | 2.516M |
Net Change In Cash | -2.780M | -122.3M |
YoY Change | -59.75% | -857.6% |
FREE CASH FLOW | ||
Cash From Operating Activities | -$101.4M | -$90.32M |
Capital Expenditures | $4.340M | $4.301M |
Free Cash Flow | -$105.7M | -$94.62M |
YoY Change | 42.31% | 16.66% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001652130 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
CY2023Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2022Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2022Q2 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
http://fasb.org/us-gaap/2023#LicenseAndServiceMember | |
us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
http://fasb.org/us-gaap/2023#LicenseAndServiceMember | ||
us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
http://fasb.org/us-gaap/2023#LicenseAndServiceMember | ||
CY2023Q2 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
http://fasb.org/us-gaap/2023#LicenseAndServiceMember | |
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-06-30 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
001-37766 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
INTELLIA THERAPEUTICS, INC. | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
36-4785571 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
40 Erie Street | ||
dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 130 | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Cambridge | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MA | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
02139 | ||
dei |
City Area Code
CityAreaCode
|
857 | ||
dei |
Local Phone Number
LocalPhoneNumber
|
285-6200 | ||
dei |
Security12b Title
Security12bTitle
|
Common Stock, par value $0.0001 per share | ||
dei |
Trading Symbol
TradingSymbol
|
NTLA | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
false | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2023Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
88490950 | |
CY2023Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
171806000 | |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
523506000 | |
CY2023Q2 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
736268000 | |
CY2022Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
669116000 | |
CY2023Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
5056000 | |
CY2022Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
3768000 | |
CY2023Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
26485000 | |
CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
20407000 | |
CY2023Q2 | us-gaap |
Assets Current
AssetsCurrent
|
939615000 | |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
1216797000 | |
CY2023Q2 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
164013000 | |
CY2022Q4 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
69338000 | |
CY2023Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
33194000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
27921000 | |
CY2023Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
123550000 | |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
133076000 | |
CY2023Q2 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
21837000 | |
CY2022Q4 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
32455000 | |
CY2023Q2 | us-gaap |
Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
|
41031000 | |
CY2022Q4 | us-gaap |
Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
|
40527000 | |
CY2023Q2 | us-gaap |
Assets
Assets
|
1323240000 | |
CY2022Q4 | us-gaap |
Assets
Assets
|
1520114000 | |
CY2023Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
11634000 | |
CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
5154000 | |
CY2023Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
49534000 | |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
60876000 | |
CY2023Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
16750000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
16685000 | |
CY2023Q2 | ntla |
Contract With Customer Liability Related Party Current
ContractWithCustomerLiabilityRelatedPartyCurrent
|
2900000 | |
CY2022Q4 | ntla |
Contract With Customer Liability Related Party Current
ContractWithCustomerLiabilityRelatedPartyCurrent
|
19900000 | |
CY2023Q2 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
21933000 | |
CY2022Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
43839000 | |
CY2023Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
99851000 | |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
126554000 | |
CY2023Q2 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
12919000 | |
CY2022Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
19932000 | |
CY2023Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
105582000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
114018000 | |
CY2023Q2 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
0 | |
CY2022Q4 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
24026000 | |
CY2023Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
240000000 | |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
120000000 | |
CY2023Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
88347634 | |
CY2023Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
88347634 | |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
87103007 | |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
87103007 | |
CY2023Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
9000 | |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
9000 | |
CY2023Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
2512741000 | |
CY2022Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
2420223000 | |
CY2023Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-3868000 | |
CY2022Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-7461000 | |
CY2023Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1403994000 | |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1177187000 | |
CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1104888000 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1235584000 | |
CY2023Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1323240000 | |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1520114000 | |
CY2023Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
13594000 | |
CY2022Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
14030000 | |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
26200000 | ||
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
25282000 | ||
CY2023Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
115276000 | |
CY2022Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
90199000 | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
212392000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
223294000 | ||
CY2023Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
30652000 | |
CY2022Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
22132000 | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
58100000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
44535000 | ||
CY2023Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
145928000 | |
CY2022Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
112331000 | |
us-gaap |
Costs And Expenses
CostsAndExpenses
|
270492000 | ||
us-gaap |
Costs And Expenses
CostsAndExpenses
|
267829000 | ||
CY2023Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-132334000 | |
CY2022Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-98301000 | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-244292000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-242547000 | ||
CY2023Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
12653000 | |
CY2022Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
703000 | |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
24633000 | ||
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1243000 | ||
CY2023Q2 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-4000000 | |
CY2022Q2 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-3252000 | |
us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-7048000 | ||
us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-5997000 | ||
CY2023Q2 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
0 | |
CY2022Q2 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-172000 | |
us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
100000 | ||
us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
249000 | ||
CY2023Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
8653000 | |
CY2022Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-2377000 | |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
17485000 | ||
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-5003000 | ||
CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-123681000 | |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-100678000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-226807000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-247550000 | ||
CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.4 | |
CY2023Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.4 | |
CY2022Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.33 | |
CY2022Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.33 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-2.58 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-2.58 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-3.29 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-3.29 | ||
CY2023Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
88185000 | |
CY2023Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
88185000 | |
CY2022Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
75823000 | |
CY2022Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
75823000 | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
87979000 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
87979000 | ||
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
75282000 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
75282000 | ||
CY2023Q2 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-1482000 | |
CY2022Q2 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-932000 | |
us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
1507000 | ||
us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-6060000 | ||
CY2023Q2 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
|
292000 | |
CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
|
-560000 | |
us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
|
2086000 | ||
us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
|
-862000 | ||
CY2023Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-124871000 | |
CY2022Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-102170000 | |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-223214000 | ||
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-254472000 | ||
CY2023Q2 | ntla |
Revenue From Related Party
RevenueFromRelatedParty
|
5792000 | |
CY2022Q2 | ntla |
Revenue From Related Party
RevenueFromRelatedParty
|
7767000 | |
ntla |
Revenue From Related Party
RevenueFromRelatedParty
|
10727000 | ||
ntla |
Revenue From Related Party
RevenueFromRelatedParty
|
13151000 | ||
us-gaap |
Profit Loss
ProfitLoss
|
-226807000 | ||
us-gaap |
Profit Loss
ProfitLoss
|
-247550000 | ||
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
4220000 | ||
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
3591000 | ||
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-15000 | ||
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
0 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
63655000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
41559000 | ||
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
11667000 | ||
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-4428000 | ||
us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-7048000 | ||
us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-5997000 | ||
us-gaap |
Equity Method Investment Sold Carrying Amount
EquityMethodInvestmentSoldCarryingAmount
|
5656000 | ||
us-gaap |
Equity Method Investment Sold Carrying Amount
EquityMethodInvestmentSoldCarryingAmount
|
5656000 | ||
us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
100000 | ||
us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
249000 | ||
ntla |
In Process Research And Development Charge
InProcessResearchAndDevelopmentCharge
|
0 | ||
ntla |
In Process Research And Development Charge
InProcessResearchAndDevelopmentCharge
|
55990000 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
1289000 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
824000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
6078000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-434000 | ||
ntla |
Increase Decrease In Operating Right Of Use Assets
IncreaseDecreaseInOperatingRightOfUseAssets
|
-9373000 | ||
ntla |
Increase Decrease In Operating Right Of Use Assets
IncreaseDecreaseInOperatingRightOfUseAssets
|
-5368000 | ||
us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
503000 | ||
us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
802000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
6287000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-3710000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-12525000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-721000 | ||
us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-28919000 | ||
us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-30099000 | ||
ntla |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-8217000 | ||
ntla |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-4458000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-199651000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-164892000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
8133000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
5409000 | ||
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
625319000 | ||
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
31524000 | ||
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
476666000 | ||
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
224583000 | ||
us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
287000 | ||
us-gaap |
Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
|
0 | ||
us-gaap |
Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
|
44832000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-156786000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
142818000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1220000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
13262000 | ||
us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
2051000 | ||
us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
1068000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
4737000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
53215000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-351700000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
31141000 | ||
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
535463000 | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
125486000 | |
CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
183763000 | |
CY2022Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
156627000 | |
CY2023Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
171806000 | |
CY2022Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
147781000 | |
CY2023Q2 | us-gaap |
Restricted Cash Equivalents
RestrictedCashEquivalents
|
11957000 | |
CY2022Q2 | us-gaap |
Restricted Cash Equivalents
RestrictedCashEquivalents
|
8846000 | |
CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
183763000 | |
CY2022Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
156627000 | |
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
2998000 | ||
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
3750000 | ||
CY2023Q2 | ntla |
Shares Issued For Rewrite Research Milestone Liability
SharesIssuedForRewriteResearchMilestoneLiability
|
24126000 | |
CY2022Q2 | ntla |
Shares Issued For Rewrite Research Milestone Liability
SharesIssuedForRewriteResearchMilestoneLiability
|
0 | |
CY2023Q2 | us-gaap |
Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
|
0 | |
CY2022Q2 | us-gaap |
Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
|
10541000 | |
CY2023Q2 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
902536000 | |
CY2023Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
70000 | |
CY2023Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
2325000 | |
CY2023Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
900281000 | |
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
742215000 | |
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
62000 | |
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
3823000 | |
CY2022Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
738454000 | |
us-gaap |
Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
|
0 | ||
CY2022 | us-gaap |
Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
|
0 | |
CY2023Q2 | ntla |
Available For Sales Securities Noncurrent Maturing Beyond Year Five
AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive
|
0 | |
CY2022Q4 | ntla |
Available For Sales Securities Noncurrent Maturing Beyond Year Five
AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive
|
0 | |
ntla |
Research Milestone Payments
ResearchMilestonePayments
|
25000000 | ||
CY2022Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
24026000 | |
CY2023Q2 | us-gaap |
Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
|
100000 | |
us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
-24126000 | ||
CY2023Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
0 | |
CY2022 | ntla |
Discount Rate
DiscountRate
|
0.101 | |
CY2022 | ntla |
Probability Of Achievement
ProbabilityOfAchievement
|
1 | |
CY2022 | ntla |
Projected Year Of Achievement
ProjectedYearOfAchievement
|
2023 | |
us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
23273000 | ||
us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
24443000 | ||
CY2023Q2 | ntla |
Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
|
25437000 | |
CY2022Q4 | ntla |
Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
|
32684000 | |
CY2023Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
15713000 | |
CY2022Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
21778000 | |
CY2023Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
2971000 | |
CY2022Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1457000 | |
CY2023Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
5413000 | |
CY2022Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
4957000 | |
CY2023Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
49534000 | |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
60876000 | |
CY2022Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
3768000 | |
ntla |
Increase In Accounts Receivables
IncreaseInAccountsReceivables
|
9305000 | ||
ntla |
Decrease In Accounts Receivables
DecreaseInAccountsReceivables
|
8017000 | ||
CY2023Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
5056000 | |
CY2022Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
63771000 | |
us-gaap |
Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
|
-28919000 | ||
CY2023Q2 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
34852000 | |
CY2021Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
2031000 | |
ntla |
Increase In Accounts Receivables
IncreaseInAccountsReceivables
|
4655000 | ||
ntla |
Decrease In Accounts Receivables
DecreaseInAccountsReceivables
|
3832000 | ||
CY2022Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
2854000 | |
CY2021Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
127235000 | |
us-gaap |
Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
|
-30099000 | ||
CY2022Q2 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
97136000 | |
CY2023Q2 | us-gaap |
Capitalized Contract Cost Gross
CapitalizedContractCostGross
|
0 | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
1941379 | |
ntla |
Business Combination Upfront Cash Consideration
BusinessCombinationUpfrontCashConsideration
|
43730000 | ||
ntla |
Business Combination Research Contingent Consideration Liabilities
BusinessCombinationResearchContingentConsiderationLiabilities
|
10541000 | ||
ntla |
Business Acquisition Cost Of Acquired Entity Transaction Cost
BusinessAcquisitionCostOfAcquiredEntityTransactionCost
|
1838000 | ||
us-gaap |
Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
|
56109000 | ||
CY2023Q2 | ntla |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment
|
55990000 | |
CY2023Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
|
287000 | |
CY2023Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
|
153000 | |
CY2023Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
|
321000 | |
CY2023Q2 | ntla |
Business Combination Transaction Price
BusinessCombinationTransactionPrice
|
56109000 | |
CY2023Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
36400000 | |
CY2022Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
23068000 | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
63655000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
41559000 | ||
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
70.70 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
|
2701197 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
42.45 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
493878 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
|
70.91 | ||
ntla |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
|
61694 | ||
ntla |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue
|
55.91 | ||
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
4087004 | |
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
52.23 | |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
40.75 | |
CY2022Q1 | ntla |
Number Of Tranches
NumberOfTranches
|
2 | |
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
38.7 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
42.45 | ||
CY2023Q2 | ntla |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueAmount
|
6200000 | |
ntla |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueAmount
|
18300000 | ||
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
55.16 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
76.57 | ||
CY2022Q2 | ntla |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueAmount
|
1500000 | |
ntla |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueAmount
|
8000000 | ||
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
29.8 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
28.92 | ||
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
28.76 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
57.23 | ||
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
800000 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
1900000 | ||
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
10500000 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
40400000 | ||
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.041 | |
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.034 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.044 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.019 | ||
CY2023Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y7M6D | |
CY2022Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y7M6D | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y10M24D | ||
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.788 | |
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.779 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.787 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.762 | ||
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5471675 | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
49.86 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
569821 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
41 | ||
us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
78724 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
15.51 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
61755 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
95.52 | ||
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5901017 | |
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
48.99 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y10M20D | ||
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
68634000 | |
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
3848672 | |
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
40.24 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y2M8D | ||
CY2023Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
59876000 | |
CY2023Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
83100000 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
|
P1Y10M6D | ||
CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-123681000 | |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-100678000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-226807000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-247550000 | ||
CY2023Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
88185000 | |
CY2023Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
88185000 | |
CY2022Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
75823000 | |
CY2022Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
75823000 | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
87979000 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
87979000 | ||
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
75282000 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
75282000 | ||
CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.4 | |
CY2023Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.4 | |
CY2022Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.33 | |
CY2022Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.33 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-2.58 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-2.58 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-3.29 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-3.29 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9988000 | ||
CY2023Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9988000 | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7272000 | ||
CY2022Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7272000 | |
CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
62000 | |
CY2023Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
465000 | |
CY2023Q2 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
2051000 | |
CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
36400000 | |
CY2023Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-1482000 | |
CY2023Q2 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
|
292000 | |
CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-123681000 | |
CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1104888000 | |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1040244000 | |
CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
164000 | |
CY2022Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
8435000 | |
CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
18491000 | |
CY2022Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-5128000 | |
CY2022Q1 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
|
-302000 | |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-146872000 | |
CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
953754000 | |
CY2022Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
4827000 | |
CY2022Q2 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
1068000 | |
CY2022Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
23068000 | |
CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-932000 | |
CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
|
-560000 | |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-100678000 | |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
880547000 | |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
120000000 | |
CY2023Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
240000000 | |
CY2023Q2 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
2800000 | |
us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
5700000 |